Table 1.

Baseline demographic characteristics of female RA patients treated with anti-TNF

Characteristics	Values
Age, years, median (range)	57 (19–76)
Swedish, n (%)	34 (82.9)
Current smoker, n (%)	11 (28.2)
HLA-DR shared epitope positive, n (%)	26 (66.6)
ACPA positive, n (%)	29 (74.3)
Bone erosions, n (%)	18 (46.1)
DAS28, median (range)	4.79 (2.49–7.48)
28-joint swollen joint count, median (range)	6 (1–25)
28-joint tender joint count, median (range)	8 (1–28)
Prednisolone treatment, n (%)	23 (58.9)
Anti-TNF drugs, n
Infliximab	16
Etanercept	8
Adalimumab	11
Golimumab	2
Certolizumab	2
CRP, mg/L, median (range)	2 (0.5–59)
Patient global health assessment, median (range)	50 (5–100)
HAQ physical function, median (range)	0.75 (0–2.6)
Health professional global health assessment, median (range)	45 (11–82)